Wednesday, April 22

Browsing: Rhabdomyosarcoma

Research

TAK1 is a key regulator of oncogenic signaling and differentiation blockade in rhabdomyosarcoma

By NewsCancerApril 6, 20260

Malempati S, Hawkins DS. Rhabdomyosarcoma: review of the children’s oncology group (COG) soft-tissue sarcoma committee experience and rationale for current…

Survivors

NCCN Publishes New Guidelines Focusing on Pediatric Rhabdomyosarcoma

By NewsCancerFebruary 22, 20260

The National Comprehensive Cancer Network (NCCN) has recently published new practical guidelines for pediatric soft tissue sarcoma care, according to…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

AACR in 30 Seconds: Revolution Medicines data, NCI director, wildfires

HDAC8 inhibition targets STAT3–MYC axis and synergizes with Venetoclax in KMT2A-rearranged acute myeloid leukemia

Mastectomy, ET Linked to Lower LRR in Young Populations With Breast Cancer

Browsing: Rhabdomyosarcoma

TAK1 is a key regulator of oncogenic signaling and differentiation blockade in rhabdomyosarcoma

NCCN Publishes New Guidelines Focusing on Pediatric Rhabdomyosarcoma

AACR in 30 Seconds: Revolution Medicines data, NCI director, wildfires

HDAC8 inhibition targets STAT3–MYC axis and synergizes with Venetoclax in KMT2A-rearranged acute myeloid leukemia

Mastectomy, ET Linked to Lower LRR in Young Populations With Breast Cancer

Revolution Medicines previews ‘novel class’ of cancer treatments

AACR in 30 Seconds: Revolution Medicines data, NCI director, wildfires

HDAC8 inhibition targets STAT3–MYC axis and synergizes with Venetoclax in KMT2A-rearranged acute myeloid leukemia

Mastectomy, ET Linked to Lower LRR in Young Populations With Breast Cancer

Revolution Medicines previews ‘novel class’ of cancer treatments

Latest Post

AACR in 30 Seconds: Revolution Medicines data, NCI director, wildfires

HDAC8 inhibition targets STAT3–MYC axis and synergizes with Venetoclax in KMT2A-rearranged acute myeloid leukemia

Mastectomy, ET Linked to Lower LRR in Young Populations With Breast Cancer

Subscribe to Updates

What's Hot

Browsing: Rhabdomyosarcoma